J. Edward Moreno

1 week ago | sherwood.news | J. Edward Moreno

A 38-to-1 stock split sparked a rally for Regencell, but other factors are likely at play. Regencell Bioscience, a Hong Kong-based herbal medicine company that generates no revenue, has skyrocketed in value amid a rally triggered by a 38-for-1 stock split. The company, still in its research and development phase, is developing herbal medicine treatments for ADHD and autism. So far it has only bled money and generated none.

1 week ago | sherwood.news | J. Edward Moreno

Verve Therapuetics rose more than 75% in premarket trading after Eli Lilly announced that it would buy the gene-editing biotech company. The acquisition is a sign Lilly is looking for other paths to sustain growth after the patents for its blockbuster weight loss and diabetes drugs expire about a decade from now. Verve generated $32.3 million in revenue in 2024 and has not yet reported a profitable quarter.

1 week ago | sherwood.news | J. Edward Moreno

Sarepta Therapeutics is down nearly 40% in premarket trading after the company disclosed over the weekend that a second patient receiving its experimental gene therapy died of liver failure. The company said Sunday that it would halt commercial shipments of Elevidys, a muscular dystrophy gene therapy, for non-ambulatory individuals "until enhanced regimen is approved and in place,” while also pausing a clinical trial that may allow for broader use of the treatment in the future.

2 weeks ago | sherwood.news | J. Edward Moreno

When it comes to erectile dysfunction pills, telehealth companies are blurring the line between medicine and marketing. In an effort to differentiate themselves and retain customers, companies like Hims & Hers, Ro, and BlueChew are increasingly offering altered versions of standard FDA-approved medications. The practice, known as compounding, might be most evident in the plethora of erectile dysfunction and hair-loss medications now available on the platforms.

2 weeks ago | sherwood.news | J. Edward Moreno

RH is up by double digits in early trading after it reported earnings that beat Wall Street estimates, quelling some investor fears that the business was doomed by President Trump’s tariff plans. The company, formerly known as Restoration Hardware, reported earnings per share of $0.13, compared to the $0.09 loss analysts were expecting, despite slightly missing on revenue. The furniture retailer also kept its full-year outlook unchanged.